Clinical significance of Ki-67 in patients with lung adenocarcinoma in situ complicated by type 2 diabetes

Figure 1 The rates of negative (grey), weakly (blue), moderately (yellow), and strongly positive (red) Ki-67 expression in the three groups. A: Patients with acute ischemic stroke (AIS) and type 2 diabetes mellitus; B: Patients with AIS alone; C: Patients with benign pulmonary lesions.

Figure 2 The rates of strongly, moderately, and weakly positive and negative Ki-67 expression (%) in the three groups. Grey: Negative expression; Green: Weakly positive; Yellow: Moderately positive; Blue: Strongly positive. Group A: Patients with acute ischemic stroke (AIS) and type 2 diabetes mellitus; Group B: Patients with AIS alone; Group C: Patients with benign pulmonary lesions. ^aP < 0.05; ^bP < 0.01.

Figure 3 Pearson’s correlation analysis of the relationships of Ki-67 with fasting plasma glucose and glycosylated hemoglobin. A: Fasting plasma glucose; B: Glycosylated hemoglobin. FPG: Fasting plasma glucose; HbA1c: Glycosylated hemoglobin.

Figure 4 Receiver operating characteristic curve for Ki-67. The y-axis presents sensitivity (true positive rate), and the x-axis represents 1-specificity (false positive rate). The curve assesses the diagnostic performance of Ki-67, and the area under the receiver operating characteristic (ROC) curve (AUC) is 0.9112, indicating a high level of accuracy. The dotted red line represents a random guess (AUC = 0.5), and the blue ROC curve greatly surpasses this line, illustrating that Ki-67 has strong predictive power in this context. AUC: Area under the receiver operating characteristic curve.